Moderna has received FDA approval for a new flu vaccine designed for adults ages 50 and older. Learn more about this new ...

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was ...

WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 ...

Moderna shares rose 8.8% to $248.63 after mRNA-1469 advanced toward Phase 2/3 trials in the DRC targeting Bundibugyo ...

Moderna said its vaccine to protect against ebola was recommended to advance into a Phase 2/3 trial in Congo. Pending regulatory approval, Moderna's mRNA-1469 vaccine will be tested to prevent ...

Moderna, Inc. (NASDAQ: MRNA) announced that its investigational mRNA vaccine candidate, mRNA-1469, targeting Bundibugyo ebolavirus (BDBV), has been recommended to advance into a Phase 2/3 efficacy ...

Moderna (MRNA) will advance its investigational mRNA-1469 vaccine candidate against Bundibugyo ebolavirus toward a phase 2/3 efficacy study in the Democratic Republic of the Congo ...

The European Patent Office has said it has invalidated a patent held by Moderna on mRNA-based COVID-19 vaccines, the latest development in an increasingly acrimonious dispute between the company and ...

做疫苗的人都知道一个心照不宣的事实：传统疫苗开发太慢了。 从病原体分离、抗原鉴定、临床前评价到三期临床，平均要 10 到 15 年，单支疫苗的研发成本估计超过 10 亿美元。HPV 疫苗 Gardasil 从实验室到上市花了 15 年，轮状病毒疫苗 ...

Since the start of this year, Moderna (MRNA) has become the hottest stock in the S&P 500, with gains far exceeding 600%.

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA ...